for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Edwards Lifesciences Corp

EW.N

Latest Trade

219.66USD

Change

4.55(+2.12%)

Volume

781,539

Today's Range

216.35

 - 

220.00

52 Week Range

136.47

 - 

228.19

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
215.11
Open
216.35
Volume
781,539
3M AVG Volume
24.67
Today's High
220.00
Today's Low
216.35
52 Week High
228.19
52 Week Low
136.47
Shares Out (MIL)
207.97
Market Cap (MIL)
44,736.26
Forward P/E
40.25
Dividend (Yield %)
--

Next Event

Q3 2019 Edwards Lifesciences Corp Earnings Release

Latest Developments

More

FDA Identifies Edwards Lifesciences' Sapien Heart Valve Recall As Class I

Edwards Sapien 3 Tavr Receives FDA Approval For Low-Risk Patients

Edwards Lifesciences Files For Potential Mixed Shelf Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Industry

Medical Equipment & Supplies

Contact Info

1 Edwards Way

+1.949.2502500

https://www.edwards.com

Executive Leadership

Michael A. Mussallem

Chairman of the Board, Chief Executive Officer

Scott B. Ullem

Chief Financial Officer, Corporate Vice President

Jean-Luc Lemercier

Corporate Vice President - EMEA (Europe, Middle East and Africa)

Donald E. Bobo

Corporate Vice President - Strategy and Corporate Development

Catherine M. Szyman

Corporate Vice President - Critical Care

Key Stats

2.18 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

3.0K

2017

3.4K

2018

3.8K

2019(E)

4.2K
EPS (USD)

2016

2.890

2017

3.800

2018

4.700

2019(E)

5.345
Price To Earnings (TTM)
59.28
Price To Sales (TTM)
11.29
Price To Book (MRQ)
12.78
Price To Cash Flow (TTM)
52.77
Total Debt To Equity (MRQ)
16.97
LT Debt To Equity (MRQ)
16.97
Return on Investment (TTM)
16.34
Return on Equity (TTM)
13.61

Latest News

FDA pegs Edwards Lifesciences Sapien delivery system recall as severest

The U.S. health regulator on Thursday categorized the recall of Edwards Lifesciences Corp's Sapien 3 Ultra delivery system as extremely serious, highlighting health risks associated with its use, but the products will remain on the market.

Edwards Lifesciences recalls delivery system for Sapien heart valves

Medical device maker Edwards Lifesciences Corp is recalling its Sapien 3 Ultra delivery system after burst balloons during implantation led to several injuries and a death, said the U.S. Food and Drug Administration on Thursday.

UPDATE 1-Edwards Lifesciences, Medtronic heart valves win U.S. approval for expanded use

Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday.

Edwards Lifesciences, Medtronic heart valves win FDA approval for expanded use

Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the FDA said on Friday.

FDA ties three deaths to Edwards Lifesciences' recalled heart devices

The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

FDA says three deaths related to Edwards Lifesciences' recalled heart devices

The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been...

Edwards Lifesciences beats on revenue but forecast lags estimates

U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below analysts' forecasts.

Edward Lifesciences pays Boston Scientific $180 million to end patent row

Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

BRIEF-Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards Sapien 3 Valve

* REAL-WORLD EVIDENCE CONFIRMS CLINICAL TRIAL OUTCOMES FOR PATIENTS TREATED WITH EDWARDS SAPIEN 3 VALVE

BRIEF-Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

* EDWARDS LIFESCIENCES ENTERS INTO ACCELERATED SHARE REPURCHASE AGREEMENT

BRIEF-Edwards Lifesciences Says Entered Into Credit Agreement To Establish Multi-Currency Unsecured Revolving Credit Facility - SEC Filing

* EDWARDS LIFESCIENCES SAYS ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY - SEC FILING

BRIEF-Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

* EDWARDS GRANTED CE MARK FOR FIRST TRANSCATHETER TRICUSPID THERAPY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

Edwards Lifesciences Corp's <EW.N> first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc <MDT.N>.

BRIEF-Edwards Lifesciences Reports Q1 Earnings Of $0.96/Share

* QUARTERLY TOTAL ADJUSTED SALES $937.5 MILLION, UP 9.3 PERCENT

Edwards Lifesciences reports 1.3 pct rise in quarterly sales

Medical device maker Edwards Lifesciences Corp reported a 1.3 percent rise in first-quarter revenue on Tuesday on higher demand for transcatheter heart valves, its biggest business.

BRIEF-Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

* BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES

BRIEF-Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016

* EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GUuNcF) Further company coverage:

BRIEF-Boston Scientific says co prevails in UK Edwards Lifesciences Litigation​

* BOSTON SCIENTIFIC CORP SAYS BOSTON SCIENTIFIC PREVAILS IN U.K. EDWARDS LIFESCIENCES LITIGATION

BRIEF-Edwards Lifesciences Prevails In U.S. Patent Office Review

* EDWARDS PREVAILS IN U.S. PATENT OFFICE REVIEW THAT FINDS BOSTON SCIENTIFIC TRANSCATHETER VALVE PATENT CLAIMS INVALID Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up